CEACAM5 and breast cancer: In summary, our work contributes to the investigation toward establishing whether CEACAM-targeting 2A3-CAR T-cells can potentially be used as an effective immunotherapeutic agent against CEACAM5/6-expressing human malignancies, such as pancreatic or mammary cancers.